GTC Biotherapeutics, the Framingham-based transgenic drug manufacturer, has reached an agreement to regain the rights to commercialize one of its top products, ATryn.
GTC has been working with Lundbeck Inc., a subsidiary of H. Lundbeck A/S of Denmark to commercialize, market and distribute the drug. GTC announced it has reached an agreement by which it will reclaim the commercialization of the drug after a six-month transition period. Lundbeck will receive royalties on net sales beginning in two years.
ATryn is a government-approved drug for treating a rare blood clotting disorder.
GTC has recently changed executive leadership, which you can read more about here.
